Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Systematic Review Article

Current Clinical Psychopharmacology in Borderline Personality Disorder

Author(s): Antonio Del Casale*, Luca Bonanni, Paride Bargagna, Francesco Novelli, Federica Fiaschè, Marco Paolini, Francesca Forcina, Gaia Anibaldi, Francesca Natalia Cortese, Alessia Iannuccelli, Barbara Adriani, Roberto Brugnoli, Paolo Girardi, Joel Paris and Maurizio Pompili

Volume 19 , Issue 10 , 2021

Published on: 10 June, 2021

Page: [1760 - 1779] Pages: 20

DOI: 10.2174/1570159X19666210610092958

Price: $65

Abstract

Background: Patients with Borderline Personality Disorder (BPD) manifest affective and behavioral symptoms causing personal distress, relationship difficulties, and reduced quality of life with global functioning impairment, mainly when the disease takes an unfavorable course. A substantial amount of healthcare costs is dedicated to addressing these issues. Many BPD patients receive medications, mostly those who do not respond to psychological interventions.

Objective: Our aim was to assess the efficacy of the most used strategies of pharmacological interventions in BPD with a comprehensive overview of the field.

Methods: We searched the PubMed database for papers focused on the most used psychotropic drugs for BPD. We included randomized controlled trials and open studies in adult patients with BPD, focusing on the efficacy and tolerability of single classes of drugs with respect to specific clinical presentations that may occur during the course of BPD.

Results: Specific second-generation antipsychotics (SGAs) or serotonergic antidepressants can be effective for different core symptoms of BPD, mainly including mood symptoms, anxiety, and impulse dyscontrol. Some atypical antipsychotics can also be effective for psychotic and dissociative symptoms. Specific antiepileptics can be useful in some cases in treating different BPD symptoms, mainly including mood instability, impulsiveness, and anger.

Conclusion: No medication is currently approved for BPD, and clinicians should carefully assess the benefits and risks of drug treatment. Further studies are needed to identify specific personalized treatment strategies, also considering the clinical heterogeneity and possible comorbidities of BPD.

Keywords: Borderline personality disorder, affective instability, drug treatment, impulsiveness, anger, atypical antipsychotics, mood stabilizers, antidepressants.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy